Safety of repotrectinib in children and teens in Japan with NTRK fusion-positive tumors
Tracks side effects of repotrectinib in young people with NTRK fusion-positive solid tumors.
Plain-language title generated from the registry record
Registry title: Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan
Key facts
- Where
- Minato-ku and Tokyo, JapanSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 4 and 17 years old?
Source: NCT07755826, who can take part
Where in Japan
- CMIC Co., Ltd.Minato-ku, JapanTaking people
- EPS CorporationTokyo, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07755826
- Record updated
- 10 August 2026
- Original description
This study will collect safety information during routine medical care for children and adolescents in Japan who have been diagnosed with NTRK fusion-positive advanced or recurrent solid tumors who start treatment with repotrectinib. The study will describe how often side effects occur during treatment, with special attention to central nervous system disorders, interstitial lung disease, and fractures.Read full original descriptionShow less
Repotrectinib Post-Marketing Surveillance in Pediatric Patients (Age 4 to < 18) With NTRK Fusion-Positive Advanced/Recurrent Solid Tumors in Japan
This study will collect safety information during routine medical care for children and adolescents in Japan who have been diagnosed with NTRK fusion-positive advanced or recurrent solid tumors who start treatment with repotrectinib. The study will describe how often side effects occur during treatment, with special attention to central nervous system disorders, interstitial lung disease, and fractures.
Inclusion: All pediatric NTRK fusion-positive, advanced or recurrent solid tumors patients (age 4 to < 18) who received Repotrectinib for the approved indications at medical institutions in Japan during enrollment period (for 6 years after approval for this application) will be enrolled in this Post-Marketing Study.
Exclusion: Participants receiving repotrectinib for an off-label indication.